

Literaturliste

Winzige Wirkstoffe

Dr. Pascal Mensah

Erschienen in der CO.med 9/2018, S. 26–27.

- [1] Turner, M. D., Nedjai, B., Hurst, T. & Pennington, D. J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochim. Biophys. Acta - Mol. Cell Res.* **1843**, 2563–2582 (2014).
- [2] Sporn, M. B. The importance of context in cytokine action. *Kidney Int.* **51**, 1352–1354 (1997).
- [3] Kleiner, G., Marcuzzi, A., Zanin, V., Monasta, L. & Zauli, G. Cytokine levels in the serum of healthy subjects. *Mediat. Inflamm* **2013**, 434010 (2013).
- [4] Bernasconi, S. Low Dose Medicine: theoretical background and scientific evidence. *Ital. J. Pediatr.* **44**, 23 (2018).
- [5] McCormack, J. P., Allan, G. M. & Virani, A. S. Is bigger better? An argument for very low starting doses. *Cmaj* **183**, 65–69 (2011).
- [6] Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. *Nat. Rev. Immunol.* **15**, 283–294 (2015).
- [7] Saadoun, D. *et al.* Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. *N. Engl. J. Med.* **365**, 2067–2077 (2011).
- [8] Koreth, J. *et al.* Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. *N. Engl. J. Med.* **365**, 2055–2066 (2011).
- [9] Castela, E. *et al.* Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata. *JAMA Dermatology* **150**, 748-751 (2014).
- [10] Rosenzweig, M. *et al.* Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. *J. Autoimmun.* **58**, 48–58 (2015).
- [11] Hartemann, A. *et al.* Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol.* **1**, 295–305 (2013).
- [12] Mizui, M. & Tsokos, G. C. Low-Dose IL-2 in the Treatment of Lupus. *Curr. Rheumatol. Rep.* **18**, 68 (2016).
- [13] Dwyer, C. J., Ward, N. C., Pugliese, A. & Malek, T. R. Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2. *Curr. Diab. Rep.* **16**, 46 (2016).
- [14] Hirakawa, M. *et al.* Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cell. *JCI Insight* **1**, 1–18 (2016).

- [15] Ito, S. *et al.* Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. *Mol. Ther.* **22**, 1388–1395 (2014).
- [16] Poli, A. *et al.* CD56bright natural killer (NK) cells: An important NK cell subset. *Immunology* **126**, 458–465 (2009).
- [17] Martin-Martin, L. S. *et al.* An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. *Drug Des. Devel. Ther.* **11**, 985–994 (2017).
- [18] Montero, A. J. *et al.* Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. *Leuk. Lymphoma* **47**, 2049–2054 (2006).
- [19] Shi, J. & Wei, P. Low-dose interleukin 8 induces the adhesion, migration and invasion of the gastric cancer SGC-7902 cell line. *Oncol. Lett.* **10**, 2871–2877 (2015).
- [20] Dai, Q., Li, Y., Zhang, F., Yu, H. & Wang, X. Therapeutic effect of low-dose IL-18 combined with IL-10 on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of Th2 responses. *Rheumatol. Int.* **29**, 615–622 (2009).
- [21] Hivert, B., Pascal, L. B., Trauet, J., Yakoub-Agha, I. & Labalette, M. Low Dose Interleukin-7 Supplementation Increases Intrinsic Cord Blood T Cell Survival without Enhancing Proliferative Alloresponses. *Blood* **120**, 4353 (2012).
- [22] Radice, E., Miranda, V. & Bellone, G. Low-doses of sequential-kinetic-activated interferon- γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. *Int. Immunopharmacol.* **19**, 66–73 (2014).
- [23] Burnett, A. F., Biju, P. G., Lui, H. & Hauer-Jensen, M. Oral interleukin 11 as a countermeasure to lethal total-body irradiation in a murine model. *Radiat. Res.* **180**, 595–602 (2013).
- [24] Polman, C. *et al.* Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. *Mult. Scler. J.* **9**, 342–348 (2003).
- [25] Fleischmann, W. R. & Koren, S. Systemic Effects of Orally Administered Interferons and Interleukin-2. *J. Interf. Cytokine Res.* **19**, 829–839 (1999).
- [26] Tompkins, W. A. Immunomodulation and Therapeutic Effects of the Oral Use of Interferon-alpha: Mechanism of Action. *J. Interf. Cytokine Res.* **19**, 817–828 (1999).
- [27] Bosio, E., Beilharz, M. W., Watson, M. W. & Lawson, C. M. Efficacy of Low-Dose Oral Use of Type I Interferon in Cytomegalovirus Infections In Vivo. *J. Interf. Cytokine Res.* **19**, 869–876 (1999).
- [28] Gariboldi, S. *et al.* Low dose oral administration of cytokines for treatment of allergic asthma. *Pulm. Pharmacol. Ther.* **22**, 497–510 (2009).
- [29] Roberti, M. L. *et al.* Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. *J. Biol. Regul. Homeost. Agents* **28**, 133–139 (2014).

- [30] Hanson, M. L. *et al.* Oral Delivery of IL27 Recombinant Bacteria Attenuates Immune Colitis in Mice. *Gastroenterology* **146**, 210–221 (2014).
- [31] Yates, M., Keat, A. & Gaffney, K. Do low-dose anti-TNF regimens have a role in patients with ankylosing spondylitis? *Rheumatol. (United Kingdom)* **55**, 769–772 (2016).